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 Rucker and colleagues examine the rela-
tionship between distance to a neph-
rologist and the likelihood of seeing a 
nephrologist in a study published in this 
issue of  Kidney International . 1 In this 
study, increasing distance from a neph-
rologist has a  ‘ protective eff ect ’ against 
seeing a nephrologist. Unfortunately, it 
is also protective from undergoing 
assessment of certain key parameters 
that are considered markers of quality of 
care, such as hemoglobin A1c and urine 
albumin measurements. And most sig-
nifi cantly, distance from a nephro logist 
is associated with a greater risk of hospi-
talization, a longer hospitalization, and a 
greater mortality risk. 
 This is entirely consistent with and 
complementary to multiple studies exam-
ining a similar association in end-stage 
renal disease patients that suggest that 
patients who saw a nephrologist before 
the initiation of dialysis had greater sur-
vival than patients who had limited or no 
care by a nephrologist before starting. 2,3 
Although one could further discuss the 
limitations of the study by Rucker  et al. , 1 
given its consistency with these similar 
studies and with the related concept of 
quality of care, it doesn ’ t make sense to 
consume a Commentary detailing the 
limitations of the conclusion that seeing 
a doctor is a good thing. 
 Th e question of the potential mecha-
nisms is, however, very relevant, because 
they could shed light on ways to approach 
the solution. Consideration of the issues 
related to health-care reform in the 
United States has provided the opportu-
nity to examine how the process of 
health-care delivery aff ects outcomes. In 
a health-care system such as exists in the 
United States, it is easy to conjecture that 
fi nancial barriers limiting access to health 
care might be a major driving force. 
However, in Canada, with its national 
health-care service, the fi nancial barriers 
should be isolated to a great extent, 
allowing us to examine the barriers asso-
ciated with other obstacles, such as phys-
ical distance and perception. Additionally, 
as people who were farther from neph-
rologists were not necessarily poorer, 
individual poverty, which is frequently 
discussed in the context of access to 
health care, is not playing a signifi cant 
role or is not the sole contributor. 
 Factors that deserve consideration 
as contributors include perceptions of 
value as well as communication between 
primary-care physicians and the nephro-
logy community. If there is a perception 
that at some point the increasing dis-
tance to a nephrologist outweighs the 
potential benefi t of seeing a nephrolo-
gist, then it becomes important to deter-
mine how this misperception occurred 
and how it should be approached. Are 
there lessons to be learned from other 
subspecialists in internal medicine? 
Although each subspecialty of internal 
medicine is clearly diff erent, some com-
monalities of many can be recognized. 
Oncology, for example, has provided 
clear recommendations regarding who 
needs to be screened for what types of 
cancer. Following the identifi cation of a 
malignancy, the vast majority of physi-
cians are likely to entirely defer the ther-
apy to oncologists. Cardiology has 
similarly clear reco mmendations for 
screening, but many primary-care physi-
cians may feel signifi cantly more com-
fortable with the therapies available to 
treat cardiac disease than with chemo-
therapy. Consi dered in that light, neph-
rology screening and treatment (for 
example, the care of the chronic kidney 
disease patient) is far more like cardiol-
ogy than like onco logy. Clear guidelines 
outlining patients at risk and screening 
recommendations exist, 4 yet diff erences, 
as identified by Rucker  et al. , 1 still 
remain and translate into real diff erences 
in outcomes. 
 There may be a perception that 
because therapies for chronic kidney 
disease (CKD) are not specific to CKD, 
particularly in those with diabetes or 
hypertension, CKD could be a designa-
tion that merely labels a patient at high 
risk for cardiovascular disease rather 
than being a unique entity. 5 The two 
are not mutually exclusive, but the per-
ception that they are might minimize 
the perceived risk and thus might not 
be in patients ’ best interest. Failure to 
appreciate the full magnitude of the 
relationship between abnormalities in 
renal parameters (for example, esti-
mated glomerular filtration rate or 
urine albumin excretion) and cardio-
vascular disease may result in a failure 
to achieve the increased vigilance 
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regarding cardiovascular disease that 
CKD patients require. The analysis by 
Rucker  et al. 1 suggests that screening 
and, possibly, therapies are not provided 
as frequently in the absence of nephrol-
ogy care and that this translates to dif-
ferences in important clinical outcomes. 
There may not be anything magical 
about sitting in an offi  ce with a neph-
rologist, other than the full recognition 
of the magnitude by which a patient ’ s 
risk is increased by the presence of 
kidney disease. 
 Th e considerable predictive value of 
microalbuminuria as a marker of risk, 
and its incrementally, if not extensively, 
greater power as a public-health target 
above and beyond markers such as cho-
lesterol, have recently been recog-
nized. 6,7 Perhaps nephrology needs to 
pattern itself aft er cardiology and its 
success in making  ‘ good cholesterol ’ and 
 ‘ bad cholesterol ’ household words. Car-
diologists have had tremendous success 
in driving home the public-service mes-
sage of the correlations between lipid 
levels and outcomes, as well as the even 
more powerful message that interven-
tions in lipid levels improve outcomes. 
Th e decrement in cardiovascular death 
that is due to primary prevention is tes-
timony to that success. 8 We are now in 
the wonderful position of having a sim-
ple urine test with suffi  cient evidence 
correlating it with outcomes, and of 
having demonstrated that treatment 
improves outcomes. Arguably, a urine 
test for protein is simpler to perform 
than a serum cholesterol measurement 
and can be done in far more resource-
limited settings. 
 The cynic (or perhaps the realist) 
would suggest that a large part of the 
success of cardiologists in the education 
of the health-care workforce as well as 
the public regarding the utility of meas-
uring and treating high cholesterol may 
have been driven by pharmaceutical 
companies with dedicated treatments for 
this valid intermediate outcome. Unfor-
tunately, as articulated above, the regi-
mens that lower the risk associated with 
albuminuria are not entirely dedicated 
to treating albuminuria. Rather, this 
marker of cardiovascular and renal risk 
has many potential contributors and 
many potential treatments. Th erefore, 
success by the same mechanism used in 
cardiology may not materialize. 
 We also need to reach out to the patients 
( Figure 1 ). We need to make creatinine 
and proteinuria household words as rec-
ognizable as the concepts of good choles-
terol and bad cholesterol. For patients 
who are regular consumers of health 
care, this education may help with com-
pliance. Th e disease state is certainly as 
widespread and as important as high 
cholesterol and heart disease and is argu-
ably more complex. Because CKD is not 
fi xed with a single pill, education regard-
ing the multiple contributors that require 
multiple fronts of attack (blood pressure, 
diabetes, and so on) is even more essen-
tial. But more importantly, this education 
may help  ‘ bring the mountain to Moham-
med. ’ We must not forget the large bur-
den of disease that exists among patients 
who are not regular consumers of health 
care. Th e data demonstrating the number 
of people with unrecognized CKD 9 may 
suggest that the estimates of association 
of risk described by Rucker  et al. 1 dra-
matically underestimate both the burden 
and the risk. 
 Th e relationships are clearly defi ned. 
Seeing a doctor is a good thing. Having 
the doctor do all of the necessary screen-
ing, prevention, and treatment is a good 
thing. Knowing why one needs to follow 
his or her doctor ’ s advice is a good thing. 
Now that we have identifi ed that there 
are systemic issues preventing patients 
from seeing a subspecialist and getting 
appropriate screening, we need a 
 coordinated effort to understand and 
reverse the cause. Nephrologists need to 
take excellent care of the patients who 
come to see us, but we also need to take 
actions to reach out to those who do not 
come, or do not know that they need to 
come. Nephrologists and primary-care 
physicians need to communicate to best 
determine how responsibilities will be 
split or shared at a local level. And every-
one involved in health care, from research 
to provision to manufacturing, needs to 
work together to reach out to the public. 
It will take a village, but the challenge is 
far from insurmountable. Patterning our 
attack aft er the successes in heart disease 
and hypertension will help not only to 
prevent disease but also to save lives. 
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 Prevention of sudden cardiac 
arrest in dialysis patients: can we 
do more to improve outcomes ? 
 Bessie A.  Young 1 , 2 
 Sudden cardiac arrest (SCA) is a leading cause of cardiac-associated 
mortality in dialysis patients. Risk factors unique to hemodialysis 
patients include abnormal electrolytes, large-volume ultrafiltration, and 
prior history of cardiac disease. Few randomized controlled trials of 
standard cardiac interventions have been completed in dialysis patients. 
Observational studies suggest that modification of the dialysis 
prescription may be one place to intervene. Prospective research is 
needed to determine mechanisms of SCA in hemodialysis patients. 
 Kidney International (2011)  79, 147 – 149.  doi: 10.1038/ki.2010.433 
 Cardiac disease remains the primary cause 
of death among dialysis patients (84.5 per 
1000 patient-years) and accounts for 
39.2 % of all deaths. 1 Mortality associated 
with sudden cardiac death or sudden car-
diac arrest (SCA) accounts for 58.6 % of 
cardiac-related deaths (49.5 per 1000 
patient-years). 1 As expected, SCA-associ-
ated death is higher among the elderly and 
those with a cardiac history and among 
whites compared with blacks and other 
minorities. 1 In addition, SCA is known to 
occur more oft en on the fi rst dialysis day 
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aft er a 2-day hiatus, 2,3 with the risk being 
highest during and immediately after 
dialysis. 4 SCA is five- to 15-fold more 
likely to result from either ventricular 
fi brillation or ventricular tachycardia dur-
ing or immediately aft er dialysis, whereas 
a pulseless electrical activity arrest is more 
likely to occur before dialysis. 3 Rates of 
sudden death per dialysis session range 
from 3.4 in 100,000 3 to 7.0 in 100,000 5 
dialysis sessions in the outpatient setting 
and to 12.5 in 100,000 dialysis sessions in 
hospital-based dialysis units. 5 
 Risk factors associated with SCA 
include older age, 6 history of underlying 
diabetes, 6,7 increased inflammation, 8 
recent hospitalization, 6 low-potassium 
dialysate, 6 malnutrition, 6 use of a cathe-
ter for dialysis access, 6 left  ventricular 
hypertrophy, 9 increased levels of brain 
natriuretic peptide or N-terminal-pro-
B-type natriuretic peptide (nT-pro-BNP), 10 
rapid changes in electrolytes or large-
volume fl uid removal, and prior history 
of cardiac disease or arrhythmia. 4,6 In a 
landmark paper, Karnik and colleagues 
reported that a low-potassium bath of 0 
or 1 mequiv. per liter was associated with 
a greater risk of cardiac arrest (17.1 % 
versus 8.8 % ); however, low-K   +   dialysate 
baths did not account for all cases of car-
diac arrest. 6 Additional proposed SCA 
triggers include reduced left  ventricular 
function, ventricular ectopy, interstitial 
fi brosis due to chronic uremia, calcium 
and phosphate deposition, chronic fl uid 
overload, and generalized electrical 
instability due to fl uid shift s, acid / base 
abnormalities, and other electrolyte 
abnormalities. 11 – 13 Myocardial stunning, 
which is thought to occur with each dialysis 
session and is due to excessive volume 
and electrolyte shift s, may also contrib-
ute to the increased risk of SCA in dial-
ysis patients. 13,14 
 Few randomized controlled trials have 
evaluated interventions aimed at reducing 
SCA in dialysis patients. Observational 
data suggest that use of beta-blockers, 
angiotensin-converting enzyme inhibi-
tors, or angiotensin receptor blockers has 
been associated with decreased overall 
mortality. 15 In addition, automatic defi -
brillator placement in dialysis units has 
not been shown to be associated with 
improved survival of hemodialysis 
patients aft er SCA. 3,16 No randomized 
controlled trial of implantable cardiac 
defi brillators (ICDs) in dialysis patients 
has ever been completed; however, obser-
vational studies have shown that ICD 
placement was associated with a 42 % 
reduction in mortality in comparison with 
those without ICD placement. 17 Implant-
able defi brillators are sorely underutilized 
in dialysis patients, 17,18 and the Implant-
able Cardioverter Defi brillators in Dialysis 
Patients (ICD2) trial is a current rand-
omized controlled trial enrolling approx-
imately 200 dialysis patients aged 50 – 80 
years with prevention of SCA as the pri-
mary end point. 19 
 Now, Pun and colleagues 20 (this issue) 
describe a case-control study that evalu-
ated potentially modifi able risk factors for 
SCA among a large cohort of dialysis 
patients from 2002 to 2005. Among 43,200 
DaVita / Gambro dialysis patients, 784 wit-
nessed SCAs were documented for an 
